Journal Article (Journal Article;Review)

Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyridine derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y(12) receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

Full Text

Duke Authors

Cited Authors

  • Tantry, US; Bliden, KP; Gurbel, PA

Published Date

  • December 2006

Published In

Volume / Issue

  • 15 / 12

Start / End Page

  • 1627 - 1633

PubMed ID

  • 17107286

Electronic International Standard Serial Number (EISSN)

  • 1744-7658

Digital Object Identifier (DOI)

  • 10.1517/13543784.15.12.1627


  • eng

Conference Location

  • England